Hi there. My name is Ryan Dinse. I’m a pretty lucky guy.
Because I’m essentially given free reign (and substantial research resources) here at Port Phillip Publishing to chase ‘moon-shot’ investment stories.
Stories that don’t just give you a shot at gains in the hundreds of percent.
But gains that could lead to exponential returns.
Returns that could literally make you rich from just one stock play.
I say I’m lucky because there are few professional investors who are allowed the time and resources to chase such stories. (I call them investment ‘collision points’.)
Mainly because 99% of them don’t pan out.
The very nature of this kind of uber-speculative investing means that you often find yourself at a dead end.
But sometimes…very rarely…you find yourself staring at your whiteboard littered with scribbled stock names, post-it notes, price charts, printed links and medical journal articles…and a tingle goes down your spine.
There really is something here.
And no one seems to have cottoned on yet…
I’ve been following such a story since October last year.
I’ve kept quiet on it until now. Because no one I can see is pursuing this avenue.
The research I’ve collated is now so compelling, I’ve convinced the higher-ups here at PPP to let me share it with you in this free e-letter in the coming days.
It’s a big story. Epic in scope.
So, it’s going to take me a few days to unwrap it for you.
I’ve been given the chance to do that in this e-letter over the next week or so.
If you’re a speculative investor partial to taking the odd risk in the hopes of a massive potential payoff, strap yourself in.
Even if you’re not, I’m pretty sure you’ll find what we dig into over the next few days intriguing.
Let’s start at the very beginning…
The greatest investment (and science) story ever told?
In the late 1980s, a cadre of ambitious biologists began planning a bold mission.
They set out to sequence every single one of the three billion pairs of ‘letters’ in the human genome.
It was a mission that was laughed at outright in science circles.
One of the key players was James Watson, who had helped discover the very existence of the double-helical structure of DNA.
Watson said at the time:
‘It was very divisive, a lot of people said no, it’s just too big, too boring, the time hasn’t come…at that time we had some viral DNAs, we had about 100,000 [DNA base pairs]. When you talked about [sequencing] humans it was a 10,000 times bigger project.’
Some believed it would take the better part of a century to complete.
Others believed there simply wasn’t enough money in the world to fund it.
(It ended up costing US$3.8 billion).
But the group of biologist dreamers persevered.
And, on 1 October 1990, the Human Genome Project (HGP) was born…
[Click to open new window]
Photo taken at a 1989 planning meeting. James Watson top row, centre, Francis Collins third from the left in the same row.
As I say, the primary goal was not a small one.
Sequencing the entire genetic code of a whole organism.
That organism being: us.
It remains the largest ever world-collaborative project. Approximately 20 universities and research institutions got involved from the US, the UK, Japan, France, Germany and China. (Although it was solely funded by the American government.)
It was a ‘moon-shot’ project that basically catapulted biotechnology and pharmaceutical fields (plus a whole host of other scientific industries) into a whole new era of R&D, over the course of just 15 years.
It also made early investors of genomic stocks pioneering in this field eye-wateringly rich.
(We’ll get to that in a second. And this is a very important point. Because if my research is correct, a new genomic project of equal importance is going to cause a new medical step-change between now and 2030. And a new set of unheard-of stocks are waiting in the wings to take advantage…)
But back to the Human Genome Project…
‘A resource of inestimable value…’
The HGP is where biology ‘went big.’
The importance — and potential spin-offs — of such a project were apparent very early on. As Watson said back in 1986:
‘To [human geneticists], the possession of the complete human DNA sequence would be a resource of inestimable value. To have it within our grasp and not go for it strikes them as an act of gross irresponsibility to society.’
Essentially, they were setting out to translate The Book of Life.
Before the HGP was complete, only 100,000 DNA base pairs were known to science.
The HGP was setting out to make that 10,000 times bigger.
To say it would revolutionise genetics and medicine is some understatement.
As UK Prime Minister Tony Blair said when the project was nearing completion:
‘Let us be in no doubt about what we are witnessing today: a revolution in medical science whose implications far surpass even the discovery of antibiotics.’
On April 14, 2003, the Human Genome Project was completed.
And, in the 15 years since, the sequenced genome has unlocked development of numerous crucial genomic technologies.
It has led to huge innovations in molecular biology, chemistry, physics, robotics and computation.
And it has led to some stunning breakthroughs in medicine that simply would not have been possible otherwise.
We can now do genetic tests that tell us IN ADVANCE if we’re likely to get a certain disease.
We can test babies for up to 50 severe, inherited but treatable genetic diseases.
We can treat one of the most common genetic diseases, cystic fibrosis, with an amazingly effective drug called G551D.
We can predict if a transplanted heart might be rejected by a patient.
And we can learn from our own genes what the best tailored cancer treatment strategy is likely to be.
All of this was very hard to predict in the early 2000s.
Great wealth was created by the HGP as well.
In the first 20 years following its launch, the Human Genome Project generated $796 billion in economic activity in the US, according to a 2011 report by the Battelle Memorial Institute.
But here’s the point I want to stress…
If, 15 years ago, you managed to predict what might spin-off from the Human Genome Project…and which stocks might benefit…
You could have potentially made a GENOMIC FORTUNE
Illumina is a company now known as one of the pillars of genomic research.
An early investment in them could have made you over 28,000%.
Illumina was not alone…
- Celgene went from 51 cents to $142
- NeoGenomics went from 20 cents to $11.24
- BioMarin Pharmaceutical Inc went from $4 to $146
- Regeneron went from $7 to $548
- Shire PLC went from $15 to $266
- Mesoblast went from $7.75 to $50
- Biogen Inc went from $28 to $409
- AveXis, Inc went from $17 to $217
- BeiGene went from $24 to $192
- Sangamo Therapeutics went from 50 cents to $25
- Bluebird Bio went from $19 to $231
- Agilent Technologies went from $9 to $63
- Celladon went from $4 to $59
As I keep saying in my research, great ‘collision points’ in history — this one being between genomics and medicine — are few and far between.
They are very, very hard to detect and predict in the early stages.
But if you CAN predict these collision points…chart what their possible outcomes might be…and identify the up-and-coming stocks attached to them…
Well, you can make a serious amount of money from just a few investments.
Now here’s the thing.
While the HGP has achieved a great deal in a very short time, there are some who are still let down by the early promises.
Those promises were that we would be able to tackle all sorts of physical and mental illnesses at a genetic level.
That the sequencing of the human genome would take a substantial slice out of human suffering. And unlock the mysteries of everything from schizophrenia to Parkinson’s.
But, after 15 years, that cancer cure still alludes us.
In an interview, Eric Green, director of the United States’ National Genome Research Institute, even admitted, ‘I feel bad if our enthusiasm and euphoria over completing the genome project was misinterpreted to mean cures 10 years later.’
Which brings me to the main point of this little primer on the Human Genome Project.
Few people know this, but a second ‘great genomic project’ is underway.
It has received hardly any press (so far).
And what press it has gotten appears to be missing the point entirely about what this project is aiming for…and what it could lead to.
If I’m right, this project, once complete, could finally please those who feel let down by the early promises from the HGP biologists.
Put simply, it could finally finish what the Human Genome Project started.
But it can’t do it without the collaborative efforts of not just dozens of scientists around the world, but of a clutch of currently unknown listed companies.
We are nearing another great genomic ‘collision point’.
Untold riches could be made by private investors who wrap their heads around it before everyone else. And who own the right stocks before most people have even heard of them.
Like I say, no one seems to be doing substantial research…at least from an investment perspective…into this new project.
But I’ve been on this story all year.
And what I’ve discovered will blow your mind.
Editor, Exponential Stock Investor